Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 35861632.
- Also identified by DOI 10.1158/1078-0432.CCR-22-1626 and PMC identifier 9481674.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tafasitamab and lenalidomide were approved for second-line treatment of diffuse large B-cell lymphoma (DLBCL) based on a single-arm phase II study. This combination was superior to routine immunochemotherapy regimens when comparing matched observational cohorts. "Synthetic" control groups may support use of novel DLBCL therapies in the absence of randomized studies. See related article by Nowakowski et al., p. 4003.
Medical subject headings
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin